To the end of March the maker of Durex condoms and Scholl foot products posted pre-tax profit of £39.1m up from a loss of £2.9m last year. Sales rose 5% to to £623.9m from £592.4m.
SSL said that following a review of the group's operations, it is focusing resources on its consumer healthcare businesses such as Durex and Scholl brands, while disposing of the medical business, as well as the industrial gloves business.
The group said the process of selling the medical business is now well underway and has generated a substantial level of interest.
SSL will develop its OTC portfolio to include new opportunities within the headlice treatment, analgesics and indigestion remedies markets.
The group said that the new year had begun satisfactorily and it was optimistic it can complete major disposals and improve the profitability of its consumer business.